Pharmacovigilance Outsourcing: What MAHs Can Delegate and What They Must Control

As safety data volumes grow, pharmaceutical companies face increasing pressure to maintain effective pharmacovigilance operations across multiple markets. Different regulatory requirements, expanding patient populations, and the need for specialised expertise can make fully internal PV processes difficult to scale. Pharmacovigilance outsourcing allows MAHs to access specialised safety services, technology, and operational capacity while managing changing workloads. However, delegation does not remove the MAH’s responsibility for regulatory compliance, data integrity, or patient safety. Effective outsourcing, therefore, requires a clear understanding of which activities can be delegated and which functions, decisions, and oversight responsibilities must remain under MAH control.

What Is Pharmacovigilance Outsourcing?

Pharmacovigilance outsourcing means transferring selected safety activities, or an entire set of PV processes, to an external service provider or contract research organisation (CRO). The scope can vary from specific operational tasks to full-service support across multiple markets. In a functional model, a provider manages defined activities such as case processing, data collection, or literature monitoring. A hybrid approach combines internal capabilities with outsourced services. Full-service models can cover a broader range of pharmacovigilance operations, from individual case processing to aggregate reporting and signal detection. The choice depends on the MAH’s resources, risk profile, and compliance expectations. However, outsourcing does not transfer the MAH’s regulatory responsibility. The MAH remains accountable for ensuring appropriate oversight, quality, and compliance with applicable regulatory requirements, even when day-to-day activities are performed externally.

Why Do MAHs Outsource Pharmacovigilance Activities?

MAHs may outsource PV activities when internal teams face increasing workloads or lack specialised resources. Growing case volumes can make routine case processing and adverse event reporting difficult to manage with existing staff. Market expansion can also create new compliance expectations, especially when companies enter countries with different regulatory requirements.

External service providers can offer local expertise, established safety protocols, and specialised technology without requiring the MAH to build these capabilities internally. This can be particularly useful when safety workloads fluctuate during clinical development, product launches, or post-marketing surveillance.

Outsourcing can also help pharma companies address shortages of experienced PV specialists. Providers may offer dedicated teams for case processing, literature monitoring, data management, or regulatory reporting. Access to established infrastructure can support cost efficiency and enhance efficiency when appropriately governed.

However, operational convenience should not determine the outsourcing model alone. MAHs should assess which activities can be delegated and which decisions, controls, and core competencies must remain under internal oversight.

Which Pharmacovigilance Activities Can Be Outsourced?

MAHs can delegate many routine PV activities while retaining oversight of critical decisions and compliance responsibilities.

Operational Pharmacovigilance Activities

Commonly outsourced activities include ICSR management, case intake, triage, data entry, medical coding, follow-up, quality control, and literature screening. MAHs may also outsource pharmacovigilance literature monitoring to support ongoing identification of relevant safety information across scientific and local sources.

Specialised and Strategic PV Activities

External providers can also support:

• Signal detection and aggregate reporting
• Risk evaluation and safety database management
• Regulatory reporting and support for risk management plans

Some providers offer specialised expertise for specific therapeutic areas, markets, or regulatory requirements. The scope should match the MAH’s internal capabilities, compliance expectations, and risk profile. Strategic decisions involving significant safety concerns, safety signals, or mitigation strategies may still require direct MAH oversight.

What MAHs Must Control When PV Activities Are Outsourced

Outsourcing does not mean losing control over the pharmacovigilance system. MAHs remain responsible for ensuring that delegated activities meet regulatory requirements and support patient safety. Clear governance is therefore essential, from contractual arrangements to ongoing vendor oversight.

Key areas requiring MAH control include:

• Roles, responsibilities, and contractual arrangements
• Quality system and compliance oversight
• Safety data exchange and regulatory timelines
• PSMF documentation and QPPV oversight
• Vendor audits and inspection readiness

Roles, Responsibilities, and Contractual Arrangements

The MAH should clearly define who performs each PV activity, who makes safety-related decisions, and who is responsible for regulatory reporting. Contracts should specify timelines, safety data exchange procedures, escalation routes, and responsibilities for follow-up. Pharmacovigilance agreements can help establish these expectations between the MAH and service provider. Where needed, pharmacovigilance consultancy services can also support governance, compliance assessments, and oversight of complex PV processes.

Quality System and Compliance Oversight

The MAH should maintain visibility into the provider’s quality system and performance. This includes monitoring SOP compliance, quality metrics, deviations, CAPAs, and performance trends. Regular review helps identify emerging safety issues or process weaknesses before they affect regulatory compliance. Delegating an operational process does not remove the MAH’s responsibility for quality control. Oversight should therefore be proportionate to the risks associated with the outsourced activity and its potential impact on patient safety.

Safety Data Exchange and Regulatory Timelines

Safety information must flow between the MAH and the service provider through defined, controlled processes. Agreements should establish how adverse events, follow-up information, and other drug safety data are exchanged. They should also identify who monitors reporting deadlines and how delays, missing information, or data discrepancies are escalated. Clear procedures for timely reporting are especially important when multiple organisations contribute to the same safety workflow. The MAH should be able to verify that regulatory reporting obligations are consistently met.

PSMF Documentation and QPPV Oversight

Outsourced activities should be accurately reflected in the MAH’s pharmacovigilance system documentation and PSMF. The documentation should show which processes are delegated and how the MAH maintains oversight. The QPPV also needs sufficient visibility into outsourced activities to oversee the safety system effectively. This includes access to relevant information, performance data, quality findings, and significant safety issues. Current subcontracting arrangements should be clearly documented, including the relevant roles and responsibilities.

Vendor Audits and Inspection Readiness

Vendor oversight should continue after the initial qualification of a service provider. MAHs should evaluate how outsourced processes perform over time through appropriate monitoring, routine audits, and risk-based assessments. Audit findings should be documented, tracked, and followed through with CAPA where necessary. The MAH should also maintain evidence that outsourced activities are adequately controlled and can be explained during inspections. Effective vendor oversight supports inspection readiness and demonstrates that the MAH retains appropriate control over its pharmacovigilance system.

Common Risks of Pharmacovigilance Outsourcing

Outsourcing can introduce risks when responsibilities, communication channels, or quality controls are not clearly defined. One common problem is an unclear division of responsibilities between the MAH and the service provider. This can create gaps in data collection, case processing, or regulatory reporting.

Fragmented communication can also delay the exchange of important safety information. A provider may receive adverse reactions or follow-up data without the MAH receiving them within the required timeframe. Such delays can affect timely reporting and signal detection.

Another risk is inadequate vendor oversight. Without appropriate performance monitoring, deviations or recurring quality problems may remain unnoticed. Inconsistent SOPs across different providers can further complicate pharmacovigilance processes, particularly when several vendors contribute to the same workflow.

Documentation gaps create additional compliance risks. Missing records of decisions, data transfers, or corrective actions can make it difficult to demonstrate data integrity during an audit or inspection.

Finally, relying on several disconnected vendors can increase operational complexity. Without effective coordination, MAHs may face duplicated work, inconsistent data, unclear escalation routes, or difficulty maintaining an efficient pharmacovigilance system.

How to Choose a Pharmacovigilance Outsourcing Partner

Choosing a service provider requires more than comparing costs. MAHs should assess regulatory and therapeutic expertise, geographical coverage, and the provider’s quality management system. Key considerations include SOP alignment, auditability, data traceability, technology capabilities, reporting KPIs, and scalability. Clear communication and escalation procedures are also essential. Providers should demonstrate experience with applicable global standards and regulatory bodies, as well as the capacity to support changing workloads. MAHs can also consider established pharmacovigilance services when they need specialised expertise without having to build additional internal infrastructure.

Full Outsourcing or a Hybrid PV Model?

MAHs can choose between full outsourcing and a hybrid PV model depending on their resources, product portfolio, and governance capabilities. Neither model is universally better. The appropriate approach depends on which functions the company can effectively manage internally and where external support adds the most value.

Full outsourcing transfers most operational PV activities to an external provider. This can reduce the internal workload and provide access to established infrastructure, specialised expertise, and scalable teams. However, greater provider dependence makes strong governance, communication, and vendor oversight especially important.

A hybrid model allows the MAH to retain critical functions and internal expertise while selectively delegating labour-intensive processes. This can provide greater control over key decisions while allowing external teams to handle activities such as case processing or literature monitoring. However, hybrid models require particularly clear boundaries of responsibility. Individual safety workflows can also be outsourced separately when this better fits the MAH’s operating model.

The best approach should balance control, flexibility, cost savings, and the need to maintain high-quality outsourced pharmacovigilance processes.

Pharmacovigilance Outsourcing Does Not Mean Outsourcing Responsibility

Outsourcing can help MAHs scale pharmacovigilance operations, access specialised expertise, and manage changing workloads. However, delegation does not remove the MAH’s ultimate responsibility for the pharmacovigilance system. The MAH must maintain appropriate oversight of outsourced activities, including quality, data integrity, regulatory reporting, and compliance with applicable requirements.

Effective governance depends on clear contractual arrangements, defined responsibilities, reliable exchange of safety data, and appropriate vendor oversight. The MAH should also maintain sufficient documentation and ensure that the QPPV has the visibility needed to oversee the system. Risk-based audits and ongoing performance monitoring can help identify weaknesses before they affect patient safety.

A well-designed outsourcing model should therefore provide operational flexibility without losing control. Whether activities are fully outsourced or divided between internal teams and external providers, accountability, quality oversight, and regulatory compliance must remain central to the MAH’s pharmacovigilance strategy.